Literature DB >> 31906936

Survival of a case of Bacillus cereus meningitis with brain abscess presenting as immune reconstitution syndrome after febrile neutropenia - a case report and literature review.

Yusuke Koizumi1,2, Takafumi Okuno3, Hitoshi Minamiguchi3, Keiko Hodohara3, Hiroshige Mikamo4, Akira Andoh3.   

Abstract

BACKGROUND: Bacillus cereus sometimes causes central nervous system infection, especially in compromised hosts. In cases of meningitis arising during neutropenia, CSF abnormalities tend to be subtle and can be easily overlooked, and mortality rate is high. We report a survived case of B. cereus meningitis/brain abscess in severe neutropenia, presenting as immune reconstitution syndrome. CASE
PRESENTATION: A 54-year-old Japanese female with acute myelogenous leukemia developed B. cereus bacteremia and meningitis during consolidation chemotherapy. At the onset, she presented with mild meningism. She had marked leukocytopenia (WBC <100/μL, neutrophils 0/μL) and lumbar puncture yielded only mild pleocytosis. She was transferred to intensive care unit, and meropenem, linezolid and vancomycin was started. With intensive therapy, she recovered and once became afebrile. On day 19, however, her fever, meningism and consciousness level dramatically worsened despite recovery of bone marrow function. The antimicrobial chemotherapy was continued and finally she was cured with no complications.
CONCLUSIONS: With early diagnosis and prompt initiation and of antibiotics, the case was successfully treated without any sequelae. It is important to remember that, even under optimal antimicrobial therapy, bone marrow recovery can cause transient reaggravation of the disease. In such cases, timely and appropriate evaluation should be done to make the clinical decision to change, continue, or intensify treatment.

Entities:  

Keywords:  Bacillus cereus; Bacteremia; Febrile neutropenia; Immune reconstitution syndrome; Meningitis

Mesh:

Substances:

Year:  2020        PMID: 31906936      PMCID: PMC6945728          DOI: 10.1186/s12879-019-4753-1

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


Background

Bacillus cereus is a Gram positive, aerobic facultative, spore-forming, rod-shaped bacterium. It is motile, catalase positive and ubiquitous, found in air, soil, water, and food [1]. Because of the ubiquitous distribution of B. cereus in food products, the bacterium is ingested in small numbers and becomes part of the transitory human intestinal flora [2]. Traditionally, the detection of Bacillus species in sterile samples has been regarded as contamination. However, the organism has the potential to cause severe infectious diseases in immunocompromised hosts [1]. Herein, we report a case of B. cereus meningitis with brain abscess, arising in the setting of neutropenia, and presenting as immune reconstitution syndrome after bone marrow recovery.

Case presentation

A 54-year-old Japanese female was diagnosed with acute myeloid leukemia (AML). Complete remission was achieved after induction chemotherapy, but 14 months later the disease relapsed. During the re-induction chemotherapy (FLAGM; fludarabine, cytarabine, granulocyte colony stimulating factor, and mitoxantrone), she experienced severe septic shock caused by Klebsiellla pneumoniae bacteremia requiring intensive care. During the consolidation therapy (high dose cytarabine), oral polymyxin B, sulfamethoxazole/trimethoprim, voriconazole, and acyclovir were administered as prophylaxis. On day 18 of consolidation chemotherapy (day 1 of infection), she complained of fever and chills. Meropenem 3 g/day was started after blood culture sampling. On day 2, headache and nausea appeared. Diarrhea was absent, and the vital signs were as follows: blood pressure 124/67 mmHg, heart rate 86 bpm, and body temperature 39.5 °C. At this time, she was conscious and lucid. Neurologically, no abnormal focal signs, including nuchal rigidity, were noted. Laboratory tests showed marked leukocytopenia (WBC < 100/μL, neutrophils 0/μL) with slight C-reactive protein elevation (1.32 mg/dL). The blood culture detected a Gram-positive rod-shaped bacterium on day 2, and the pathogen was identified as B. cereus on day 4. The strain was resistant to penicillin and quinolones, but sensitive to carbapenems, vancomycin, and linezolid. On day 3, disorientation, slurred speech, and confusion appeared. Slight nuchal rigidity was observed, and the neck flexion test was positive. Although meningitis was suggested, lumbar puncture was not performed because of severe thrombocytopenia (21,000/μL). Instead, linezolid (1200 mg/day), vancomycin (targeted trough of 20 mg/dL), and acyclovir (30 mg/kg/day) were administered in addition to high dose meropenem (6 g/day). On day 5, she was transferred to the intensive care unit because of shock. At this time, lumbar puncture yielded the following results: opening pressure: 18 cmH2O; cells: 43/mm3 (mononuclear cells dominant, with no abnormal cells); glucose: 31 mg/dL; protein: 155 mg/dL; negative for HSV-DNA, VZV-DNA, CMV-DNA, HHV-6 DNA, Cryptococcus-Antigen and WT-1 (Wilms Tumor-1). Cerebrospinal fluid (CSF) culture was negative, but B. cereus PCR was positive, leading to the diagnosis as B. cereus meningitis. With inotropic agents, deep sedation, and antimicrobials, she recovered and became afebrile. On day 19, however, her fever, meningism and consciousness level dramatically worsened despite recovery of bone marrow function. The CSF findings revealed markedly increased cells (2040 cells/mm3), and decreased glucose level (12 mg/dL). The CSF culture and PCR for B. cereus were both negative, and other diseases were excluded by the aforementioned examinations. Therefore, in concert with the increased leukocytes in peripheral blood and CSF, it was suggestive of immune reconstitution syndrome after B. cereus meningitis. The gadolinium enhanced magnetic resonance imaging (MRI) performed on day 15 had already detected meningeal thickening and several ring enhancement lesions. Glucocorticoid administration was not used to treat immune reconstitution syndrome. Meropenem, vancomycin, and linezolid were continued for 26, 40, and 45 days, respectively. They were stopped after CSF and MRI findings were confirmed to be normalized. On day 90, she was discharged to her home without any sequela, and her AML remains in remission for 5 years.

Discussion and conclusions

Central nervous system infections caused by B. cereus can be classified as three diseases: 1) postsurgical meningitis, ventriculitis or brain abscess, which can occur several days after a surgical procedure and often affects devices [3]; 2) neonatal meningitis or encephalitis occurring in premature neonates at 7 days of age (median, range 1–49 days) [4]; 3) necrotizing meningitis or hemorrhage in cases of severe neutropenia, predominantly affecting patients with leukemia (Table 1) [3-14].
Table 1

Three Types of Central Nervous System Bacillus cereus Infection

Post-Surgical Procedure/Device InfectionNeonatal InfectionSevere Neutropenia
Risk PopulationOmmaya reservoirPremature birth: 32 (27–36) weeksWBC count <100/uL
Post intrathecal injectionLow body weight infant:1500 (830–3760) gInduction therapy against AML
Disease OnsetSeveral days after procedures7 (1–49) days after birthAround 10 days of neutropenia
Mode of InfectionMeningitisMeningoencephalitisNecrotizing meningoencephalitis
VentriculitisCerebral hemorrhage
Brain abscessSubarachnoid hemorrhage
Clinical Course and PrognosisResponds well to antimicrobial therapyProgresses within hoursProgresses within hours
Leads to death within daysLeads to death within days
Cerebrospinal Fluid FindingsUp to 105 cells /mm3Around 102–3 cells /mm3Around 102 cells /mm3
Mortality rateLow75% (12/14 cases)79% (11/14 cases)
References33, 43, 6–14
Three Types of Central Nervous System Bacillus cereus Infection While postsurgical infections typically resolve in spite of marked CSF pleocytosis, in the order of 105 cells/mm3, the latter two infection types have very poor prognoses with mortality rate greater than 75%. Notably, in many cases of these two malicious diseases, CSF cell counts are usually less than 102 cells/mm3. Fourteen cases of neutropenia-associated B. cereus meningitis have been reported so far (Table 2). All but one case had hematological malignancies (AML: 6, acute lymphoblastic leukemia: 7, myelodysplastic syndrome: 1, aplastic anemia: 1) and all had severe neutropenia of less than 500/μL at the onset of disease. Moreover, 79% had less than 100/μL blood leukocytes, suggesting a role for severe neutropenia in the pathogenesis of this disease. The cases demonstrated mild or absent CSF pleocytosis, which is considered to be a result of both the severely immunodeficient state of the patient and the character of B. cereus infection in itself, which causes little inflammatory reaction [15].
Table 2

Clinical Characteristics of Neutropenia-Related Bacillus cereus Meningitis

Symptoms at Onset
CaseYearAgeUnderlying DiseasesWBC Count at OnsetFeverHeadacheVomitingDiarrheaAbdominal PainNeurological AbnormalitiesCNS DiseaseTreatmentOutcomeReference
1197363AML400a+ComaBrain abscessGM, OXA, CBCDead5
2198119AML<100+MeningitisGM, PCGDead6
3198867MDS/AML100a+++Meningoencephalitis/SAHGM, LM, PIPCDead7
419893ALL20+LethargyBrain abscessCP, VCM, GM, RFPAlive8
5199526AML20+Visual disturbanceMeningoencephalitis/SAHCAZDead9
6199764AML300+++Meningoencephalitis/SAHPIPC, GM, CPZ, CTX, ABPCDead10
7199720ALL0++++Speech disturbance, Sensory disturbanceCerebral infarction (basal ganglia)Dead11
8199913ALL0++Meningoencephalitis/hydrocephalusAlive, Severe sequelae11
9199915ALL0++MeningoencephalitisDead11
10199930AML<100++Delirium, hyperventilationNecrotic meningoencephalitisCAZ, AMKDead12
11199943AML<100+++++Delirium, decerebrate rigidityMeningoencephalitisCAZ, AMK → VCM, GM & othersDead12
12199914ALL<100+Delirium, epilepsy, comaMeningoencephalitisCAZ, AMK & othersDead12
13200316AA90++Nuchal rigidity, epilepsy, consciousness disturbanceMeningoencephalitisCAZ, IPM/CSDead13
14200519HD0+Confusion, epilepsy, hemiparesisMeningoencephalitisABPC, AMK, CPFX, TEIC, CLDMAlive14
Ourcase54AML<100+++disorientation, slurred speech, and confusionMeningoencephalitis/hydrocephalus brain abscessMEPM, LZD, VCMAlive

adenotes the number of neutrophils

Abbreviations: AA Aplastic anemia, ABPC Ampicillin, ALL Acute lymphoblastic leukemia, AMK Amikacin, AML Acute myelogenous leukemia, CAZ ceftazidime, CBC, carbenicillin, CLDM Clindamycin, CNS Central nervous system, CP Chloramphenicol, CPFX Ciprofloxacin, CPZ Cefoperazone, CTX Cefotaxime, GM Gentamicin, HD Hodgkin disease, IPM/CS Imipenem/cilastatin, LM Lincomycin, LZD Linezolid, MDS Myelodysplastic syndrome, MEPM Meropenem, OXA Oxacillin, PCG Penicillin G, PIPC Piperacillin, RFP Rifampin, VCM Vancomycin

Clinical Characteristics of Neutropenia-Related Bacillus cereus Meningitis adenotes the number of neutrophils Abbreviations: AA Aplastic anemia, ABPC Ampicillin, ALL Acute lymphoblastic leukemia, AMK Amikacin, AML Acute myelogenous leukemia, CAZ ceftazidime, CBC, carbenicillin, CLDM Clindamycin, CNS Central nervous system, CP Chloramphenicol, CPFX Ciprofloxacin, CPZ Cefoperazone, CTX Cefotaxime, GM Gentamicin, HD Hodgkin disease, IPM/CS Imipenem/cilastatin, LM Lincomycin, LZD Linezolid, MDS Myelodysplastic syndrome, MEPM Meropenem, OXA Oxacillin, PCG Penicillin G, PIPC Piperacillin, RFP Rifampin, VCM Vancomycin Our case shared common features with previous reports such as severe neutropenia at the onset of meningitis and the complication of brain abscesses. While those are typical findings of neutropenia associated B. cereus meningitis, there are two particular features of this report. First, with an early diagnosis and administration of a contemporary antimicrobial regimen, we were able to cure the disease without any complications. The regimen contained antibiotics with good penetrance, including linezolid, high dose meropenem, and a well-controlled dose of vancomycin that achieved a serum trough level of 20 μg/mL. This well-structured regimen was started immediately after the onset of meningitis, though the physical findings were subtle in the early phase, and CSF findings at day 5 showed only a moderate level of pleocytosis. This early diagnosis is crucial for the rapid initiation of intensive antimicrobial therapy. Second, we were able to closely track the CSF and MRI findings with the recovery of hematopoiesis. The patient’s meningitis symptoms were improving until day 19, when neutrophils rapidly increased. With the recovery of neutrophil count, a dramatic worsening of fever, consciousness and meningism was demonstrated. This could be considered as a type of immune reconstitution syndrome, though the term originally denoted the recovery of cellular immunity from AIDS or other immunosuppressive states. As shown in Fig. 1, we serially observed parameters of cellular immunity as well as neutrophil count. Interestingly, the severity of meningitis symptoms clearly synchronized with the blood neutrophil count, and the correlation is even more dramatic for CSF cells, CSF soluble interleukin-2 receptor (sIL-2R), and CSF adenosine deaminase (ADA). On day 19, the vast majority of CSF cells were polymorphonuclear cells (neutrophils). Later, CSF, sIL-2R and ADA increased, indicating that a typical inflammation cascade was ongoing. As differential diagnosis, other infections or an intracranial recurrence of AML were considered, but negative culture, cytology and clinical course were indicative of B. cereus meningitis. Therefore, we continued the antibiotics and the symptoms gradually improved.
Fig. 1

Clinical course. The figure indicates the clinical course of the patient from day 5 to day 48, when clinical symptoms resolved. The line plot shows the trend in blood leukocytes (above) and CSF cells (below). The vertical rectangle indicates the percentage of polymorphonuclear cells (red) in the CSF. On day 5, CSF showed moderate pleocytosis, with conspicuous protein increase. Antibiotic therapy was effective, leading to defervescence and neurological improvement. On day 13, however, fever and nuchal rigidity worsened. CSF findings showed 130 cells/μL with an increased proportion of polymorphonuclear cells. The MRI findings on day 15 revealed abscess lesions (arrow heads) and meningeal thickening (arrows). On day 19, meningism worsened remarkably, and CSF cells peaked at 2040 cells/μL with 98% polymorphonuclear cells. Other causes were ruled out, and meropenem, vancomycin, and linezolid were continued. Gradually, MRI and CSF findings improved and the patient was discharged without sequelae. Note that the inflammatory findings, such as CSF cells, sIL-2R, and ADA were dramatically enhanced in response to the recovery of blood leukocyte count. The reference ranges are; Blood leukocytes 3000-8000/μL, CSF cells 0–5/μL, CSF protein 10–40 mg/dL, CSF glucose 50–80 mg/dL, and CSF sIL-2R, <50 U/mL

Clinical course. The figure indicates the clinical course of the patient from day 5 to day 48, when clinical symptoms resolved. The line plot shows the trend in blood leukocytes (above) and CSF cells (below). The vertical rectangle indicates the percentage of polymorphonuclear cells (red) in the CSF. On day 5, CSF showed moderate pleocytosis, with conspicuous protein increase. Antibiotic therapy was effective, leading to defervescence and neurological improvement. On day 13, however, fever and nuchal rigidity worsened. CSF findings showed 130 cells/μL with an increased proportion of polymorphonuclear cells. The MRI findings on day 15 revealed abscess lesions (arrow heads) and meningeal thickening (arrows). On day 19, meningism worsened remarkably, and CSF cells peaked at 2040 cells/μL with 98% polymorphonuclear cells. Other causes were ruled out, and meropenem, vancomycin, and linezolid were continued. Gradually, MRI and CSF findings improved and the patient was discharged without sequelae. Note that the inflammatory findings, such as CSF cells, sIL-2R, and ADA were dramatically enhanced in response to the recovery of blood leukocyte count. The reference ranges are; Blood leukocytes 3000-8000/μL, CSF cells 0–5/μL, CSF protein 10–40 mg/dL, CSF glucose 50–80 mg/dL, and CSF sIL-2R, <50 U/mL In conclusion, we experienced a case of B. cereus meningitis with brain abscess during severe neutropenia from which the patient survived. With serial measurement of inflammatory / immunological markers, our report described the phenomenon resembling immune reconstitution syndrome, and we also proved that contemporary antimicrobial regimens can cure this severe disease. In cases of meningitis arising during neutropenia, CSF abnormalities tend to be subtle and can be easily overlooked. Because immediate diagnosis is crucial for survival, clinicians should be able to carefully recognize the symptoms and interpret the clinical data in order to rapidly initiate intensive treatment. Furthermore, it is important to remember that bone marrow recovery can cause transient reaggravation of the disease, even under optimal antimicrobial therapy. In such cases, timely and appropriate evaluation should be done to make the clinical decision to change, continue, or intensify treatment.
  15 in total

1.  Treatment of multiple brain abscesses caused by Bacillus cereus.

Authors:  H B Jenson; S R Levy; C Duncan; S Mcintosh
Journal:  Pediatr Infect Dis J       Date:  1989-11       Impact factor: 2.129

2.  Clinical spectrum of infection due to Bacillus species.

Authors:  D C Ihde; D Armstrong
Journal:  Am J Med       Date:  1973-12       Impact factor: 4.965

3.  Bacillus cereus meningitis in a patient under gnotobiotic care.

Authors:  G G Colpin; H F Guiot; R F Simonis; F E Zwaan
Journal:  Lancet       Date:  1981-09-26       Impact factor: 79.321

Review 4.  Bacillus cereus bacteremia and meningitis in immunocompromised children.

Authors:  A H Gaur; C C Patrick; J A McCullers; P M Flynn; T A Pearson; B I Razzouk; S J Thompson; J L Shenep
Journal:  Clin Infect Dis       Date:  2001-04-20       Impact factor: 9.079

Review 5.  Bacillus cereus, a volatile human pathogen.

Authors:  Edward J Bottone
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

6.  Necrotizing Bacillus cereus infection of the meninges without inflammatory reaction in a patient with acute myelogenous leukemia: a case report.

Authors:  N Motoi; T Ishida; I Nakano; N Akiyama; K Mitani; H Hirai; Y Yazaki; R Machinami
Journal:  Acta Neuropathol       Date:  1997-03       Impact factor: 17.088

7.  Fulminant septicaemic syndrome of Bacillus cereus: three case reports.

Authors:  M O Musa; M Al Douri; S Khan; T Shafi; A Al Humaidh; A M Al Rasheed
Journal:  J Infect       Date:  1999-09       Impact factor: 6.072

Review 8.  Neonatal meningoencephalitis caused by Bacillus cereus.

Authors:  Nisha Manickam; Aimee Knorr; Kenneth L Muldrew
Journal:  Pediatr Infect Dis J       Date:  2008-09       Impact factor: 2.129

9.  Meningitis due to Bacillus cereus: A case report and review of the literature.

Authors:  Michael P Stevens; Kara Elam; Gonzalo Bearman
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

10.  Fatal Bacillus cereus meningoencephalitis in an adult with acute myelogenous leukemia.

Authors:  E F Marley; N K Saini; C Venkatraman; J M Orenstein
Journal:  South Med J       Date:  1995-09       Impact factor: 0.954

View more
  5 in total

1.  Bacillus Cereus bacteremia complicated by brain abscess in a severely immunocompromised patient: Addressing importance of early recognition and challenges in diagnosis.

Authors:  David Schoenfeld; Dasom Lee; John A Arrington; John Greene; Olga Klinkova
Journal:  IDCases       Date:  2022-06-06

Review 2.  The Food Poisoning Toxins of Bacillus cereus.

Authors:  Richard Dietrich; Nadja Jessberger; Monika Ehling-Schulz; Erwin Märtlbauer; Per Einar Granum
Journal:  Toxins (Basel)       Date:  2021-01-28       Impact factor: 4.546

Review 3.  Bacterial Persister-Cells and Spores in the Food Chain: Their Potential Inactivation by Antimicrobial Peptides (AMPs).

Authors:  Shiqi Liu; Stanley Brul; Sebastian A J Zaat
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

4.  Bacillus cereus meningoencephalitis in an immunocompetent patient.

Authors:  Pichaya Tao Worapongsatitaya; Jakrapun Pupaibool
Journal:  IDCases       Date:  2022-07-20

Review 5.  Characterization of Bacillus cereus in Dairy Products in China.

Authors:  Xiao-Ye Liu; Qiao Hu; Fei Xu; Shuang-Yang Ding; Kui Zhu
Journal:  Toxins (Basel)       Date:  2020-07-14       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.